Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft

Horacio E. Adrogue, Liliana Soltero, Geoffrey A. Land, Venkataraman Ramanathan, Luan Truong, Wadi N. Suki

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Plasma cell-rich acute rejection (PCAR) is associated with poor allograft outcome in renal transplantation. Previous studies report a graft half-life of six months after a single PCAR episode. However, the management of this condition is unclear. Intravenous immunoglobulin (IVIG) therapy, by virtue of its immunomodulating properties, and its influence on B-cell maturation into plasma cells, may be a good candidate for reversing this type of rejection. We report four episodes of PCAR in two patients who responded well to IVIG with improvement in renal function.

Original languageEnglish (US)
Pages (from-to)567-569
Number of pages3
Issue number4
StatePublished - Aug 2006


  • Antibodies
  • Graft loss
  • Humoral rejection
  • Intravenous immunoglobulin
  • Plasmapheresis

ASJC Scopus subject areas

  • Transplantation
  • Immunology


Dive into the research topics of 'Immunoglobulin therapy for plasma cell-rich rejection in the renal allograft'. Together they form a unique fingerprint.

Cite this